ChicagoFit
GLP-1 Apprentice

A 2026 meta-analysis and systematic review of over 21,000 patients.
Study published in, Renal Failure , comprehensively summarizes the efficacy and safety profile of GLP-1: Meta-analysis study
Key positive findings:
1. GLP-1s reduced the risk of serious kidney events by 16% for those with kidney disease;
2. GLP-1s reduced albuminuria (protein leaking from kidney into urine), a first sign of kidney stress;
3. GLP-1s reduced major heart and stroke events by 16%;
4. GLP-1s reduced "renal sinus fat" (fat around the kidneys), which reduces the load of the heart;
5. GLP-1s reduced all-cause mortality by 17%;
6. GLP-1s reduced systemic inflammation protecting the heart, brain, and kidneys simultaneously.
Key negative findings:
1. GLP-1s increased nausea four-fold temporarily;
2. GLP-1s increased vomiting or diarrhea three-fold temporarily.
Study published in, Renal Failure , comprehensively summarizes the efficacy and safety profile of GLP-1: Meta-analysis study
Key positive findings:
1. GLP-1s reduced the risk of serious kidney events by 16% for those with kidney disease;
2. GLP-1s reduced albuminuria (protein leaking from kidney into urine), a first sign of kidney stress;
3. GLP-1s reduced major heart and stroke events by 16%;
4. GLP-1s reduced "renal sinus fat" (fat around the kidneys), which reduces the load of the heart;
5. GLP-1s reduced all-cause mortality by 17%;
6. GLP-1s reduced systemic inflammation protecting the heart, brain, and kidneys simultaneously.
Key negative findings:
1. GLP-1s increased nausea four-fold temporarily;
2. GLP-1s increased vomiting or diarrhea three-fold temporarily.